Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vaxil BioVXLLF 37 3-Year EBITDA Growth Rate is 33.30% as of Mar. 2026, which is 1% below its 10-year median of 33.50. GuruFocus rates VXLLF with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,135 Biotechnology companies, Vaxil Bio ranks better than 71.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 33.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 40.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 34.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vaxil Bio was 60.70% per year. The lowest was 15.20% per year. And the median was 33.50% per year.
Vaxil Bio (OTCPK:VXLLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vaxil Bio 3-Year EBITDA Growth Rate Related Terms
VXLLF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Vaxil Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxil Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxil Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vaxil Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 33.30% mean?
Vaxil Bio (VXLLF) has a 3-Year EBITDA Growth Rate of 33.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vaxil Bio and its competitors. This is near median its historical median of 33.50. Over the past decade, Vaxil Bio's 3-Year EBITDA Growth Rate has ranged from 15.20 to 60.70. According to the industry distribution chart, Vaxil Bio ranks #328 out of 1135 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Vaxil Bio's 3-Year EBITDA Growth Rate too high?
Vaxil Bio's current 3-Year EBITDA Growth Rate of 33.30% is near median its 10-year median of 33.50. Over the past 10 years, this metric has ranged from a low of 15.20 to a high of 60.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Vaxil Bio's value of 33.30% is 125% above this industry median. Based on the distribution chart, Vaxil Bio ranks #328 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vaxil Bio has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #328 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Vaxil Bio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Vaxil Bio's value of 33.30% is 125% above this benchmark. Historically, Vaxil Bio's own 3-Year EBITDA Growth Rate has ranged from 15.20 to 60.70 over the past decade. While the company's 10-year median is 33.50 vs. the industry median of 14.80, Vaxil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxil Bio's current 3-Year EBITDA Growth Rate of 33.30% is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vaxil Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxil Bio's current 3-Year EBITDA Growth Rate is 33.30%, which is near median its own 10-year median of 33.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current 3-Year EBITDA Growth Rate of 33.30%. The current 3-Year EBITDA Growth Rate is 33.30%, which is near median its 10-year median of 33.50 and 125% above the Biotechnology industry median of 14.80. Vaxil Bio's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current 3-Year EBITDA Growth Rate is 33.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
37GF Score
Get the complete analysis for VXLLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VXLLF has been successfully added to your 
